Back to search results
NCT05911256

A Community Health Worker/Pharmacist Team to Improve Blood Sugars in Diabetes Care Using Continuous Glucose Monitoring

Enrolling by Invitation
NAAges 25–75InterventionalTreatment
University of Massachusetts, Worcester
~318 participants
Updated 2025-10-20 on ClinicalTrials.gov
What's tested:Pharmacist OnlyContinuous Glucose Monitor (CGM)Community Health Worker (CHW)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in participant HbA1c values
Measured over 0, 3, 6, 9, and 12 months (and additional 18-month collection in first 75% of participants)

Conditions

Type 2 Diabetes

Explore related trials

Type 2 Diabetes Mellitus

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Ben Gerber, MD, MPH · PRINCIPAL_INVESTIGATOR · University of Massachusetts, Worcester

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 25-75.
History of T2DM \> 1 year.
Speak English or Spanish.
A1c ≥ 8% (within past 6 months) - with reduction if necessary based on recruitment.
eGFR (estimated glomerular filtration rate) \> 30.
Willingness to use continuous glucose monitoring (CGM) and work with a community health worker (including home visits) and clinical pharmacist.

Exclusion

Plans for weight reduction surgery or prescription weight loss medication (specific for weight loss, not GLP-1).
Current, recent, or planned use of CGM.
Current use of steroids.
Abuse of illicit drugs.
Pregnancy (or planned pregnancy).
Specific comorbidities (e.g., recent MI, TIA, CVA, malignancy, hemoglobinopathy, severe hypoglycemia, etc.).
Psychiatric disorder that may limit ability to perform study tasks
Skin changes that preclude use of sensor or allergy to adhesive.
Planning to leave geographic area within 12 months or distance from clinical site \> 20 miles.
Participation in another study.

What this trial measures

  • Change in participant HbA1c values0, 3, 6, 9, and 12 months (and additional 18-month collection in first 75% of participants)

    Participant HbA1c will be measured and obtained by finger stick using home testing kits.